IR Pharma company logo
  • Company overview
  • Technology - The drug development process at IRP, The Drug Evaluation Process, Model systems
  • Contact us
  • Respiratory Pharmacology pre-clinical drug discovery to the biopharma and pharma industries.
    975 Cornforth Drive
    Kent Science Park
    Sittingbourne, Kent ME9 8PX
    T 01795 437426
    F 01795 423440
    E info@irpharma.co.uk
    National Heart & Lung Institute
    Sir Alexander Fleming Building
    Imperial College, London SW7 2AZ
    T 01795 437426
    F 01795 423440
    E info@irpharma.co.uk

    IR Pharma Ltd - Company Overview

    IR Pharma provides the pharmaceutical industry with Respiratory Pharmacology pre-clinical drug discovery through short, focused projects and larger, wide ranging system-based discovery programmes. Timely delivery of study objectives that add value to client lead compounds and technology are high priority for the company.

    Based on the world leading academic expertise of the Respiratory Pharmacology group at the National Heart and Lung Institute, Imperial College, led by Professor Maria Belvisi and Dr Mark Birrell, the team, additionally can boast an extensive industry background. They have been providing an outstanding combination of scientific insights and practical solutions to address the pre-clinical needs of industry clients for several years.

    With the formation of IR Pharma Ltd, this expertise was placed on a commercial footing intended to provide clients with easy access to discovery expertise through a business-attuned process that is fully conversant with industry needs and timelines. The aim of the IR Pharmacology team is to provide clients with a customer friendly system, addressing their needs through provision of:

    • A responsive business interface for addressing enquiries
    • Rapid early feedback on project feasibility
    • Quick and efficient movement to contract

    The quality of the service provided by IR Pharma is endorsed by its prestigious list of past clients that have chosen the IRP team to evaluate their lead compounds and delivery technology. Projects include evaluation of drugs for treatment of the major respiratory conditions and drugs that must be delivered via the respiratory route. In addition to general mechanistic models, specific disease model are available in;

    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Disease Cough

    Whatever the problem or need, we believe IR Pharma can provide an unrivalled combination of assays, models and current scientific thinking to provide solutions that represents outstanding value.